Table 2 I-124 codrituzumab pharmacokinetics
From: I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma
Dose | Co observed %IA/L | Co estimated %IA/L | Vc (L) | T1/2 delayed (h)a | AUC based on fit (%IA × h/L) | Clearance (ml/h) | Vdss (L) |
|---|---|---|---|---|---|---|---|
10 mg (n = 14) | 32.9 ± 9.1 | 32.4 ± 9.2 | 3.399 ± 1.233 | 46.2 ± 12.58 | 1712 ± 438 | 61.8 ± 14.8 | 3.669 ± 1.281 |
2.5 mg/kg (total 130–240 mg) (n = 4) | 35.3 ± 10.3 | 35.3 ± 10.5 | 3.033 ± 0.894 | 125.7 ± 129.3 | 3429 ± 1559 | 34.2 ± 15.4 | 2.924 ± 0.830 |
5 mg/kg (total 260–400 mg) (n = 3) | 39.2 ± 5.24 | 37.3 ± 6.8 | 2.740 ± 0.464 | 99.7 ± 26.6 | 3956 ± 757 | 25.8 ± 4.5 | 3.504 ± 0.871 |